Fake Clinical Data No More: China To Criminalize Forgery
Executive Summary
China is planning to enact changes that will view the intentional forging of clinical trial and other data submitted to gain drug approvals as a criminal offence, punishable by prison terms of up to three years.
You may also be interested in...
Clinical Data Forgers Face Harsh Punishment In China
China FDA now has more solid ground to enforce GCP norms. A legal explanation from the nation's highest People's Supreme Court clarifies responsibilities of study sponsors and CROs involving in data falsification.
Bring On Clinical Studies: China Steps Up To Facilitate New Drug Entry
Allowing early stage Phase I studies, setting a 60-day period for IND approvals, and dropping a requirement for hospital to get certified, the China FDA proposes fundamental changes that would allow any qualified sites to file for approval to get studies rolling.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.